Welcome to LookChem.com Sign In|Join Free

CAS

  • or
5-Benzyluracil is a chemical compound with the molecular formula C11H10N2O2. It is an analogue of uracil, a key component of nucleic acids, with a benzyl group attached to the 5-position of the uracil ring. This modification gives 5-benzyluracil different properties compared to uracil, making it potentially useful in pharmaceutical and chemical applications.

18493-83-9

Post Buying Request

18493-83-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

18493-83-9 Usage

Uses

Used in Pharmaceutical Applications:
5-Benzyluracil is used as an anti-cancer and antiviral agent for its potential therapeutic effects. It has been studied for its ability to inhibit the enzyme dihydroorotate dehydrogenase, which is involved in the biosynthesis of pyrimidine nucleotides, a crucial process for the replication of cancer cells and viruses.
Used in Chemical Synthesis:
5-Benzyluracil is used as a starting material in organic synthesis for the production of other compounds. Its unique structure and properties make it a valuable intermediate in the synthesis of various pharmaceuticals and chemical products.
Used in Research and Development:
5-Benzyluracil is used in research and development for studying its potential applications in medicine and chemistry. Its unique properties and interactions with biological systems make it an interesting subject for further investigation and development of new therapeutic agents and chemical processes.

Check Digit Verification of cas no

The CAS Registry Mumber 18493-83-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,4,9 and 3 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 18493-83:
(7*1)+(6*8)+(5*4)+(4*9)+(3*3)+(2*8)+(1*3)=139
139 % 10 = 9
So 18493-83-9 is a valid CAS Registry Number.
InChI:InChI=1/C11H10N2O2/c14-10-9(7-12-11(15)13-10)6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H2,12,13,14,15)

18493-83-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-benzyl-1H-pyrimidine-2,4-dione

1.2 Other means of identification

Product number -
Other names 5-Benzyl-1H-pyrimidin-2,4-dion

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:18493-83-9 SDS

18493-83-9Relevant articles and documents

Synthesis of acyclic nucleoside phosphonates targeting flavin-dependent thymidylate synthase in Mycobacterium tuberculosis

Agrofoglio, Luigi A.,Becker, Hubert F.,Biteau, Nicolas G.,Lambry, Jean-Christophe,Myllykallio, Hannu,Roy, Vincent

, (2021/08/16)

Flavin-Dependent Thymidylate Synthase (FDTS) encoded by ThyX gene was discovered as a new class of thymidylate synthase involved in the de novo synthesis of dTMP named only in 30 % of human pathogenic bacteria. This target was pursed for the development of new antibacterial agents against multiresistant pathogens. We have developed a new class of ANPs based on the mimic of two natural's cofactors (dUMP and FAD) as inhibitors against Mycobacterium tuberculosis ThyX. Several synthetic efforts were performed to optimize regioselective N1-alkylation, cross-coupling metathesis and Sonogashira cross-coupling. Compound 19c showed a poor 31.8% inhibitory effect on ThyX at 200 μM.

NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS

-

Paragraph 0583, (2018/03/25)

The invention relates to novel heterocyclic compounds of general formula (I), as well as their pharmaceutically acceptable salts, and their enantiomers. The invention also relates to the use thereof as a medicinal product, preferably in the prevention and/or treatment of inflammatory diseases with a neurogenic component or use thereof as a cosmetic. The compounds of the present invention act as antagonists of the CGRP-R receptor.

Synthesis of modified uracil and cytosine nucleobases using a microwave-assisted method

Burgula, Laxmi Narayana,Radhakrishnan,Kundu, Lal Mohan

supporting information; experimental part, p. 2639 - 2642 (2012/06/30)

Modified nucleobases and nucleic acids have found many biological and pharmaceutical applications. Here we report a microwave-directed synthesis of a variety of modified uracil and cytosine nucleobases with high yields under solvent-free conditions. The reaction yields were further improved by addition of Lewis acid. The crystal structures of 5-isopropyl-6-methyluracil and 6-phenyluracil were also determined.

DNA-protein cross-linking: Model systems for pyrimidine-aromatic amino acid cross-linking

Sun, Guangxing,Fecko, Christopher J.,Nicewonger, Robert B.,Webb, Watt W.,Begley, Tadhg P.

, p. 681 - 683 (2007/10/03)

We have synthesized simple model systems to explore the possibility of photo-cross-linking between the pyrimidine bases and the side chains of the aromatic amino acids. Thymine/phenylalanine and thymine/tyrosine models gave cross-links, and thymine/tryptophan models gave complex mixtures; the cytosine/phenylalanine model was unreactive. The quantum yields for the model cross-linking reactions were 18-46 times smaller than those for thymine dimer formation. Biphotonic excitation contributes little to the yield of these reactions.

Inhibition of uridine phosphorylase: Synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2- hydroxyethoxy)methyl]-5-benzyluracils

Orr,Musso,Boswell,Kelley,Joyner,Davis,Baccanari

, p. 3850 - 3856 (2007/10/02)

A series of 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils were synthesized and tested for inhibition of murine liver uridine phosphorylase (UrdPase). Inhibitors of UrdPase are reported to enhance the chemotherapeutic utility of 5-fluoro-2'-deoxyuridine and 5-fluorouracil and to ameliorate zidovudine- induced anemia in animal models. We prepared a series of 5-aryl-substituted analogues of 5-benzylacyclouridine (BAU), a good inhibitor of UrdPase (IC50 of 0.46 μM), to develop a compound with enhanced potency and improved pharmacokinetics. The first phase of structure-activity relationship studies on a series of 32 aryl-substituted 5-benzyluracils found several 5-(3- alkoxybenzyl) analogues of 5-benzyluracil with enhanced potency. The acyclovir side chain, the (2-hydroxyethoxy)methyl group, was substituted on the more potent aryl-substituted 5-benzyluracils. The two most potent compounds, 10y (3-propoxy) and 10dd (3-sec-butoxy), were inhibitors of UrdPase with IC50s of 0.047 and 0.027 μM, respectively. Six compounds were tested in vivo for effects on steady-state concentrations of circulating uridine in rats. Plasma uridine levels were elevated 3-9-fold by compound levels that ranged from 8 to 50 μM.

Derivatives of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-phenyluracil and 5-benzyluracil synthesis and biological properties

Dziewiszek,Schinazi,Chou,Su,Dzik,Rode,Watanabe

, p. 77 - 94 (2007/10/02)

A number of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)uracil and -cytosine nucleosides substituted at the 5 position with a nitrophenyl or nitrobenzyl group were synthesized from 5-phenyl- and 5-benzyluracil via condensation of the fluorinated sugar, followed by nitration. The corresponding amino analogues were also prepared by reduction of the nitro nucleosides. The uracil nucleosides were converted into the corresponding cytosine nucleosides by way of the triazole intermediates. None of these nucleosides exhibited significant activity against herpes simplex virus type 1 in Vero cells. However, cytosine nucleosides containing the o-nitrophenyl, p-nitrophenyl, p- nitrobenzyl or p-aminobenzyl substituent were found to be toxic (even at 1 μM) to uninfected Vero cells, although they were essentially nontoxic in HL- 60 cells. The 5'-monophosphates of the uracil nucleosides were inhibitors of the reaction catalyzed by purified Ehrlich ascites carcinoma thymidylate synthase, the 5-phenyluracil nucleotides causing a strong inhibition, competitive vs dUMP, described by the K(i) value of 0.01 μM.

Process for preparing uracil derivatives

-

, (2008/06/13)

The present invention relates to a novel process for preparing uracil derivatives useful as intermediates in the synthesis of uridines having antiviral or antitumor activity or useful as coadjuvants in antiviral therapy, characterized by converting a compound of the formula II into its mesylate derivative of the formula III which is the reduced to give the desired compound of the formula I: STR1 in which R1 is H, halogen, alkyl, aryl or aralkyl.

SYNTHESIS OF 5-ALKYL SUBSTITUTED URACIL DERIVATIVES FROM BARBITURIC ACID

Candiani, Ilaria,Cabri, Walter,Bedeschi, Angelo,Martinengo, Tiziano,Penco, Sergio

, p. 875 - 879 (2007/10/02)

A new two step synthesis of 5-alkyluracil derivatives from barbituric acids is described.Regioselective mono O-mesylation of barbituric acids, followed by desulfonylation under reductive conditions, afforded uracils in high overall yield.The reductive desulfonylation step is also discussed.

REDUCTIVE DEBROMINATION OF 5-BROMOURACILS BY 1-BENZYL-1,4-DIHYDRONICOTINAMIDE

Sako, Magoichi,Hirota, Kosaku,Maki, Yoshifumi

, p. 3919 - 3922 (2007/10/02)

N(1)-Unsubstituted 5-bromouracils with or without a substituent in position 6 undergo reductive debromination with ease most likely via a one-electron transfer process upon treatment with 1-benzyl-1,4-dihydronicotinamide under thermal conditions.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 18493-83-9